דסטיניב אס.קיי 100 מג
k.s.kim international (sk- pharma) ltd., israel - dasatinib - טבליות מצופות פילם - dasatinib 100 mg - dasatinib
דסטיניב אס.קיי 140 מג
k.s.kim international (sk- pharma) ltd., israel - dasatinib - טבליות מצופות פילם - dasatinib 140 mg - dasatinib
דסטיניב אס.קיי 20 מג
k.s.kim international (sk- pharma) ltd., israel - dasatinib - טבליות מצופות פילם - dasatinib 20 mg - dasatinib
דסטיניב אס.קיי 50 מג
k.s.kim international (sk- pharma) ltd., israel - dasatinib - טבליות מצופות פילם - dasatinib 50 mg - dasatinib
דסטיניב אס.קיי 70 מג
k.s.kim international (sk- pharma) ltd., israel - dasatinib - טבליות מצופות פילם - dasatinib 70 mg - dasatinib
טייקרב
novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
גליבק 100 מ"ג כמוסות
novartis pharma services ag - imatinib as mesylate 100 mg - capsules - imatinib - treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ - cml) in chronic phase, accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist).
גליבק ® 100 מ"ג
novartis pharma services ag - imatinib as mesylate 100 mg - film coated tablets - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l
סוטנט 12.5 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
סוטנט 25 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.